Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and Nω-nitro-L-arginine-treated rats

Journal Pharmacological Sciences

Volumn 91, Issue 4, 2003, Pages 319-329

  Chino, Daisuke ^a,b   Fujita, Yukiyoshi ^a   Ishii, Kunio ^a,c   Nakayama, Koichi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

DX 9065a; Ellagic acid; Skin blood flow; Tetrodotoxin and N nitro L arginine treated rat; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DX 905A; ELLAGIC ACID; N(G) NITROARGININE; TETRODOTOXIN; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; DOPPLER FLOWMETER; DOSE RESPONSE; DRUG EFFECT; FEMORAL ARTERY; FOOT SOLE; HEMODYNAMIC PARAMETERS; HINDLIMB; INHIBITION KINETICS; MALE; MICROSCOPY; MONITORING; NONHUMAN; PROTHROMBIN TIME; RAT; RISK; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SKIN TEMPERATURE; THROMBOGENESIS; THROMBOSIS;

EID: 0038392822     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.91.319     Document Type: Article

References (34)

1. Nagahara T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, Hara T and Iwamoto M: Dibasic (amidinoaryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 37, 1200-1207 (1994)
2. Hara T, Yokoyama A, Morishima Y and Kunitada S: Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80, 99-104 (1995)
3. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T and Iwamoto M: DX 9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 71, 314-319 (1994)
4. Hara T, Yokoyama A, Tanabe K, Ishihara H and Iwamoto M: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 74, 635-639 (1995)
5. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B and Lormeau JC: DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther 276, 1030-1038 (1996)
6. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T and Matsuda T: Effects of DX-9065a, an orally, active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulatio in rats. Thromb Haemost 72, 392-396 (1994)
7. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T and Matsuda T: Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin Thromb Haemost 22, 255-259 (1996)
8. Wong PC, Crain EJ Jr, Nguan O, Watson CA and Racanelli A: Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 83, 117-126 (1996)
9. Morishima Y, Tanabe K, Terada Y, Hara T and Kunitada S: Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 78, 1366-1371 (1997)
10. Porcari AR, Chi L and Leadley R: Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors. Expert Opinion on Investigational Drugs, 9, 1595-1600 (2000)
11. G-nitro-L-arginine-treated rats. J Cardiovasc Pharmacol 35, 630-637 (2000)
12. Nunoki K and Iijima T: Modification of the baroreceptor reflex by superfision of the canine posterior hypothalamus with tetrodotoxin. Naunyn Schmiedebergs Arch Pharmacol 321, 185-189 (1982)
13. ω-Nitro-L-arginine: A potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol 176, 219-223 (1990)
14. G-nitro-L-arginine. Eur J Pharmacol 287, 49-56 (1995)
15. Bock PE, Srinivasan KR and Shore JD: Activation of intrinsic blood coagulation by allegaci acid: Insoluble ellagic acid-metal ion complexes are the activating species. Biochemistry 20, 7258-7266 (1981)
16. Hara T, Iwamoto M, Ishihara M and Tomikawa M: Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats. Haemostasis 24, 351-357 (1994)
17. De Clerck F, Goossens J, Vermylen J, Hornstra G and Reneman RS: Modification of venous stasis thrombosis in the rat by platelet-active drugs and by heparin. Arch Int Pharmacodyn Ther 222, 233-242 (1976)
18. Suehiro A, Kakishita E and Nagai K: The role of platelet hyperfunction in thrombus formation inhyperlipidemia. Thromb Res 25, 331-339 (1982)
19. Uzunova AD, Ramey ER and Ramwell PW: Gonadal hormones and pathogenesis of occlusive arterial thrombosis. Am J Physiol 234, H454-H459 (1987)
20. Piere MA and Puig-Parellada P: Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. Pharmacol Res 38, 353-356 (1998)
21. Johnson JM, Brengelmann GL, Hales JR, Vanhoutte PM and Wenger CB: Regulation of the cutaneous circulation. Fred Proc 45, 2841-2850 (1986)
22. Cooke JP, Creager MA, Osmundson PJ and Shepherd JT: Sex differences in control of cutaneous blood flow. Circulation 82, 1607-1615 (1990)
23. Imura Y, Stassen JM and Collen D: Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 261, 895-898 (1992)
24. Kawai H, Yamamoto T, Hara H and Tamao Y: Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Thromb Res 74, 185-191 (1994)
25. Umemura K, Kawai H, Ishihara H and Nakashima M: Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat, Jpn J Pharmacol 67, 253-258 (1995)
26. Moledina M, Chakir M and Grandhi PJ: A synopsis of the clinical uses of argatroban. J Thromb Thrombolys 12, 141-149 (2001)
27. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M and Tamao Y: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of tis hydrophobic carboxamide portion. Biochem Biophys Res Commun 101, 440-446 (1981)
28. Matsuo T, Kario K, Matsuda S, Yamaguchi N and Kakishita E: Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A Multicenter Clinical Trial of Argatroban. J Thromb Thrombolys 2, 131-136 (1995)
29. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ and Vlasuk GP: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 85, 805-815 (1995)
30. 1 and argatroban. J Pharmacol Exp Ther 277, 502-510 (1996)
31. Clarke RJ, Mayo G, Fitzgerald GA and Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man [see comments]. Circulation 83, 1510-1518 (1991)
32. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40, 498-530 (1990)
33. Sasaki Y, Morii S, Yamashita T and Yamamoto J: Antithrombotic effect of argatroban on the pial vessels of the rat: A study with He-Ne laser-induced thrombus formation. Haemostasis 23, 104-111 (1993)
34. Murayama N, Tanaka S, Kikuchi T, Nakaoka M and Sudo K: Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. J Pharm Biomed Anal 14, 1435-1445 (1996)